Protein Drug Stability: A Formulation Challenge
Protocols vary, but many clinics structure treatment in cycles of several weeks to a few months, with periodic reassessment to determine whether to continue, taper, or discontinue therapy
BPC-157 is not approved by the FDA or veterinary regulatory agencies for use in animals
This escalation approach is standard across GLP-1 class compounds and serves to improve gastrointestinal tolerability
Researchers should request and review certificates of analysis for every new lot, verifying that sterility testing, endotoxin levels, and benzyl alcohol concentration all meet specification
In one study, TB-500 sulfoxide, produced by monocytes upon glucocorticoid administration, was found to inhibit neutrophil chemotaxis and exhibit potent anti-inflammatory effects [9]